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Abstract
Neuropathic pain (NP) represents a common and diverse group of disorders with peripheral and/or central nervous system damage 
or dysfunction. Many patients report intractable and severe pain that is resistant to simple analgesics. The diagnosis of NP is primarily 
based on clinical evaluation rather than diagnostic tests. Distinct pain qualities in the patient’s history and findings on clinical examination, 
such as hyperalgesia and other sensory findings in an area correlating with the patient’s pain pattern are important in diagnosis. 
Various screening tools may assist in the diagnosis of NP.
A number of pathophysiological mechanisms have been identified in NP, including sodium- and calcium-channel upregulation and 
spinal cord hyperexcitability (central sensitisation).Appropriate management includes evaluation of the functional impact of NP, 
patient education and reassurance. A multi-model biopsychosocial approach that includes various nonpharmacological modalities is 
recommended. Appropriate pharmacological management is based on evidence-based recommendations that provide guidance for 
selecting first-, second- and third-line medications, alone or in combination. It is hoped that future treatment advances will improve 
the care of patients who live with NP. 
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(3):40-49
Introduction
The description of pain as a result of peripheral nerve lesions by Dr 
Weir-Mitchell in casualties of the American Civil War in 1864 is widely 
regarded as the start of the scientific approach to the features of 
neuropathic pain (NP).1 Various ideas regarding the mechanisms of NP 
were proposed by scientists in the early 1900s. However, the special 
nature of NP and its terminology only started to appear in the medical 
literature in the late 1970s.2
The International Association for the Study of Pain (IASP) defines 
pain as “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of 
such damage”. Neuropathic pain is initiated or caused by a lesion or 
dysfunction of the nervous system and is maintained by a number of 
mechanisms.3,4 Injury or insult to the nervous system may lead to long-
term structural and functional changes, resulting in altered processing 
of sensory input (central sensitisation) and hyperalgesia. Neuropathic 
pain may therefore persist long after healing of the original stimulus 
(e.g. injury) and may thus be regarded as an abnormal activation of 
pain pathways.
While most acute pain is nociceptive (i.e. a response to noxious 
stimuli), chronic pain may be nociceptive, neuropathic or of mixed 
origin. The severity of nociceptive pain (e.g. osteoarthritis) often 
correlates with the extent of tissue damage. Neuropathic pain, 
however, may be initiated by a relatively minor physical insult and 
patients may have severe pain not correlating with the extent of tissue 
damage or with significant neurological deficits. On the other hand, 
patients with clear evidence of lesions in the nervous system (e.g. 
neuropathy) may have no associated NP.5
It is estimated that as many as one in five adults with chronic pain 
will have symptoms of NP. Compared with other types of pain NP is 
generally more difficult to treat and often has a more profound impact 
on quality of life. Patients with NP often present repeatedly before an 
accurate diagnosis is made and appropriate management instituted.2,5 
The personal impact of NP is often devastating and patients mostly 
generate high health costs. In the USA, costs associated with chronic 
pain have in recent years been estimated at $150 billion annually, of 
which almost $40 billion is attributable to neuropathic pain.6
Most patients with NP respond poorly to traditional analgesics and 
many require a multidisciplinary approach. With current available 
treatments, only 30–50% of patients with NP experience meaningful 
improvement in pain and function, and a long-term commitment from 
the patient and physician are required to ensure compliance and 
appropriate outcomes.2 Viewing NP as a disease in its own right, rather 
than a symptom, is the first step towards its appropriate management. 
The aim of treatment is to assist the patient in managing the pain and 
to improve function and coping mechanisms, rather than to eliminate 
the pain.7,8
Aetiology and epidemiology
Neuropathic pain may present as a specific neuropathic pain disorder 
such as in painful diabetic polyneuropathy and postherpetic neuralgia. 
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However, NP is often not a binary phenomenon (present or absent), 
but both neuropathic and nociceptive elements may contribute to 
the patient’s pain.2 The view that chronic pain may be “more or less 
neuropathic” is supported by current opinion regarding chronic pain 
mechanisms. Clinical disorders in this category include chronic 
pain associated with HIV/AIDS, as well as chronic cancer pain and 
chronic pain of spinal origin.9 The diagnosis of pain of predominantly 
neuropathic origin (POPNO) may be simplified with the use of various 
recently developed screening tools.9–13 
Neuropathic pain may also be classified as peripheral or central, 
depending on where the nerve lesion is anatomically located 2,14,15 (see 
Table I).
Table I: Common causes of neuropathic pain
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Diabetic polyneuropathy is one of the most common complications 
of diabetes, with a prevalence of 30–50%.16 Painful diabetic 
polyneuropathy (PDPN) has a prevalence of 16–26%, and up to 80% 
of patients may have moderate or severe pain.17 Quality of life is 
significantly reduced in these patients, with restriction in daily activities 
and an association with depression and sleep disturbances.16,18 In a 
United Kingdom population study almost 40% of patients with PDPN 
had never received any treatment for pain and almost a third had been 
prescribed medication with no known efficacy in NP, e.g. nonsteroidal 
anti-inflammatory agents (NSAIDs) and paracetamol.19
Postherpetic neuralgia (PHN) is defined as pain at least one month 
after rash onset.2,7 It occurs in 9–24% of patients who have had herpes 
zoster infection. In persons older than 60 years 27–68% develop 
PHN following herpes zoster infection which may lead to disability, 
depression, sleep disturbance and social withdrawal.14 Risk factors for 
the development of PHN include older age, female gender, severity of 
acute shingles and associated acute pain, HIV infection and chronic 
corticosteroid use.7
Trigeminal neuralgia, also known as “tic douloureux”, is a NP disorder 
in the facial area. It is defined by the IASP as “a sudden, unilateral, 
severe, brief, stabbing recurrent pain in the distribution of one or 
more branches of the fifth cranial nerve.”20 It is usually associated 
with vascular compression of the trigeminal nerve, but may rarely 
be secondary to a brain tumour or multiple sclerosis. The pain is an 
extremely severe “electric shock” shooting pain lasting from seconds to 
two minutes, and it does not cross the midline. It displays a paroxysmal 
pattern triggered by non-noxious stimuli such as talking, chewing 
and teeth brushing.22 Trigeminal neuralgia has a higher prevalence in 
females, it increases with age and peaks at around 70 years. When 
the condition is diagnosed in younger individuals, it should raise the 
suspicion of secondary trigeminal neuralgia, e.g. multiple sclerosis.21,22
HIV-associated distal symmetrical polyneuropathy (DSP) is 
the most frequent neurological complication associated with HIV 
infection; it occurs in over one-third of HIV-infected patients. The most 
disabling feature of DSP is pain and it may cause severe morbidity.23 
The combined effect of potentially neurotoxic antiretroviral drugs, 
e.g. d4T and ddI, and isoniazid used for tuberculosis, may worsen 
DSP, possibly due to the combined effect of vitamin B6 deficiency 
and direct neurotoxicity. Other neurotoxic drugs used in HIV-infected 
individuals may include metronidazole and antineoplastic agents such 
as vincristine and vinblastine.23 In a recent study at a large regional 
hospital in Tshwane, on 354 ambulatory patients with confirmed 
AIDS before commencing antiretroviral therapy, 20,9% had pain of 
predominantly neuropathic origin. The pain was significantly more 
prevalent in males who had a lower CD4 count and higher viral load 
levels, and in those using antituberculosis treatment.24 Eighty per 
cent of these patients experienced moderate to severe pain (pain 
severity > 5 out of 10 on a numerical rating scale). Neuropathic pain 
is an often under-recognised and under-treated complication of HIV 
infection. Other forms of NP in HIV-infected patients may include 
postherpetic neuralgia, mononeuropathy multiplex and progressive 
polyradiculopathy.14,23
Iatrogenic neuropathic pain is probably the most important cause of 
chronic postsurgical pain.25 If nerves are injured during surgery NP 
may develop early and persist long-term in the absence of ongoing 
peripheral stimuli. Chronic pain after surgery persists in 10–50% of 
patients after common operations such as inguinal hernia repair, 
breast and thoracic surgery, and leg amputation.25,26 Early aggressive 
management of perioperative pain and surgical techniques that avoid 
nerve damage are probably important to prevent chronic postoperative 
pain. A multimodal analgesic regimen using regional blockade, 
NSAIDs, coxibs, paracetamol and other analgesics throughout the 
perioperative period may be the most effective approach.26 Other 
factors that may contribute to this phenomenon include levels of pain 
before the surgery, and genetic and psychosocial factors.25,27
Neuropathic pain is a common and important source of pain also in 
cancer patients. Common aetiologies of NP in patients with cancer 
include neural compression or infiltration, as well as neuropathies due 
to chemotherapy or radiation.14
Low back and neck pain are very common disorders, but the 
prevalence of NP contributing to low back and neck pain is unknown. 
Patients with pain of spinal origin may have both elements of 
nociceptive and neuropathic pain. A variety of nerve-damaging stimuli 
may contribute to the NP component of patients with neck and low 
back pain. Neurological symptoms and signs may escape routine 
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clinical evaluation and these patients should be examined carefully and 
comprehensively.14,28,29 In two research studies in cohorts of patients 
with low back pain where different screening tools were used, 37% and 
54,7% of patients had scores that suggested pain of predominantly 
neuropathic origin.28,29
Complex regional pain syndrome (CRPS) is indeed a complex 
disorder characterised by the development of NP after tissue trauma, 
e.g. surgery or a fracture (CRPS type 1) or after a nerve injury (CRPS 
type 2). It was previously known as reflex sympathetic dystrophy 
and causalgia. This form of NP is considered to be sympathetically 
maintained. Symptoms include skin colour changes, sweating 
asymmetry and trophic changes in the nails and skin in the presence of 
the features of NP.14,30 The health and quality of life of patients with NP 
has been shown to be severely impaired. The Health Related Quality 
of Life (SF-36) questionnaire was used in a population based sample 
of patients with chronic pain and results demonstrated poor health 
in all dimensions (physical, psychological and social) in chronic pain 
patients, in particular in individuals with NP.31 The SF-36 in patients 
with chronic NP was as low as that observed in patients with serious 
organic disease, including coronary artery disease, recent myocardial 
infarction and poorly controlled diabetes mellitus.31,32 
Diagnosing neuropathic pain
There are currently no specific objective criteria to diagnose NP and 
even questionnaires are subjective. An objective neuropathy with 
pathological changes in a nerve and even a nerve injury does not 
necessarily cause pain. It should be remembered that NP may present 
long after the initial nerve injury and that genetic, psychosocial and 
other factors are relevant in the pathogenesis.2,6,33,34
Neuropathic pain is diagnosed clinically and the patient’s report of 
specific pain qualities is important. Neuropathic pain is commonly 
associated with sleep disorders, anxiety and depression, which may 
have a significant effect on morbidity. The psychosocial history should 
include concurrent mood disorder and the impact of pain on the 
patient’s ability to work and on family life. The patient’s belief about the 
pain and maladaptive thinking patterns (e.g. “I will never get better” 
or “The situation is hopeless”) is often a reliable predictor of disability. 
A focused neurological examination should include the anatomic 
distribution of abnormal sensory signs.
Symptoms2,6,8,33
•  Assessing pain quality is important in diagnosing NP. Most patients 
have more than one pain and the following sensory descriptions 
are often used by patients with NP: “burning”, “electric shock”, 
“tingling”, “cold”, “pricking” and “lancinating”.
•  Neuropathic pain may be spontaneous (continuous or intermittent) 
or evoked in response to various stimuli. Neuropathic pain often 
worsens towards the end of day and after dark.
•  Neuropathic pain often occurs in a distribution that matches 
the level of a nerve lesion and a dermatome chart is useful in 
recognising referral patterns.
•  Common non-painful symptoms that may occur in patients with NP 
include “itching”, “crawling”, numbness” and “pins-and-needles” 
(paraesthesiae).
Signs2,3,6,7,8,33,34
•  Neuropathic pain may be present in the absence of objective 
neurological findings.
•  The neurological examination focuses on the somato-sensory 
function in the area identified through the pain history. If sensory 
abnormalities are detected in an area of nerve innervation 
correlating with the patient’s pain, it is a strong predictor for the 
diagnosis of NP.2,33
•  The sensory examination evaluates the patient’s response to 
multiple stimuli, e.g. touch, pressure, pin-prick, cold, hot and 
vibration. Sensory abnormalities may be limited to one or two of the 
above when compared at the site of pain and a control site.6,33
•  Positive sensory signs include allodynia and hyperalgesia. 
Allodynia is pain due to a stimulus that does not normally provoke 
pain; hyperalgesia is an increased response to a normally painful 
stimulus. Dynamic allodynia is when movement of a cotton swab 
or paint brush causes pain; static allodynia is when light blunt 
pressure (e.g. with a finger) causes pain; thermal allodynia is when 
cold or mildly hot stimuli are painful. Hyperalgesia often coexists 
with allodynia and these phenomena, in a patient with chronic pain, 
are strongly indicative of a neuropathic aetiology.2,35
•  Negative sensory signs are absent or diminished light touch, 
vibration, thermal or pin-prick sensations in the involved nerve 
distribution, which may also extend beyond the involved 
dermatome.6
• Other clinical signs may include:
 •  Signs of autonomic dysfunction such as skin colour changes, 
cold skin temperature and trophic changes in nails and hairs 
(indicative of sympathically maintained pain in patients with 
complex regional pain syndrome).
 •  Motor weakness around the involved nerves and diminished or 
absent tendon reflexes.6
 •  Residual scars revealed after skin examination (due to previous 
herpes zoster infection) or the skin changes associated with 
diabetes mellitus.
 •  Localised muscle tenderness and myofascial trigger points 
(indicative of secondary myofascial pain syndrome).6,33,36
A common clinical presentation of NP is allodynia, combined with 
tingling and numbness (sensory loss) at the site of pain.2,7,36 Patients 
may be confused by their sensory experiences – a patient may be 
both numb to a pinprick but very sensitive to light touch (allodynia) in 
the same nerve distribution.33 Abnormal sensory findings in a pattern 
consistent with proposed nervous system disease or injury strongly 
supports a diagnosis of NP.9
Special investigations
Laboratory studies are mostly not diagnostic but may assist in 
detecting a treatable lesion, e.g. nerve compression. Detailed 
diagnostic testing is mostly inappropriate and too expensive for routine 
clinical use.2,6,7,33 Special investigations include nerve conduction 
velocity testing (NCV), electromyography (EMG), magnetic resonance 
imaging (MRI) and quantitative sensory testing (QST). Although these 
investigations may rarely confirm or exclude a nerve lesion they are 
often normal in patients with NP, while many patients with abnormal 
studies have no pain. EMG and NCV studies assess only large nerve 
fibres that have very little involvement in pain transmission.2,3,6,7,33 
It is therefore wrong to label a patient with NP as “malingering” or 
“psychogenic” in the absence of positive neurophysiological or imaging 
studies.
Screening tools
Primary care physicians often have time constraints that preclude 
a meticulous neurological examination in patients with NP, and 
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hence it may be difficult to detect the presence of a nerve lesion. 
In this scenario, screening tools have been used to distinguish 
between neuropathic and nociceptive pain. The Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS) pain scale was the 
first of these scales; it consisted of five symptoms and two clinical 
examination items.10,29 The LANSS scale has been tested and 
validated in several clinical settings with around 80–85% accuracy 
when compared with expert clinical evaluation.2,9,38,39 Other scales that 
have since been developed and validated include the Neuropathic Pain 
Questionnaire (NPQ) and the Douleur Neuropathique (DN4) (see Table 
II). These questionnaires enable the clinician to decide if NP is the 
“dominant pain mechanism” in a patient with chronic pain. Screening 
tools are a useful indicator of possible NP but fail to identify 10–20% of 
patients with NP, and therefore cannot replace clinical assessment.10
Table II: DN4 questionnaire12
DN4 questionnaire
Complete this questionnaire by ticking one answer for each item in the four 
questions below:
PATIENT INTERVIEW




2 – Painful cold
3 – Electric shocks
Question 2: Is the pain associated with one or more of the following 
symptoms in the same area?
Yes No
4 – Tingling
5 – Pins and needles
6 – Numbness
7 – Itching 
EXAMINATION OF THE PATIENT
Question 3: Is the pain located in an area where the physical examination 
may reveal one or more of the following characteristics?
Yes No
8 – Hypoaesthesia to touch
9 – Hypoaesthesia to prick
Question 4: In the painful area, can the pain be caused or increased by:
Yes No
10 – Brushing
Mechanisms of neuropathic pain
The underlying feature in NP is the presence of damage or a lesion 
to some component of the sensory nervous system. This may be the 
consequence of inflammation, ischaemia, tumour invasion, nutritional 
deficits, nerve trauma or compression, metabolic disturbance or 
cytotoxic agents. These neuropathic pain syndromes share various 
overlapping pathogenetic mechanisms.41
Normal transmission of pain impulses is through the Aδ- and C-
afferent fibres to the dorsal horn in the spinal cord. In the dorsal horn, 
neurotransmitters such as substance P and glutamate are activated to 
transfer pain impulses to the postsynaptic neuron. The dorsal horn can 
modulate this input, allowing excitation or inhibition, and the net result 
is transmitted via the ascending tract to higher brain centres where the 
pain experience is constructed in the pain matrix. Inhibitory signals are 
sent from the brain to the dorsal horn in the spinal cord (descending 
pathways) to modulate the pain experience. The descending pathways 
release various neurotransmitters such as norepinephrine (NE), 
serotonin (5-HT) and gamma-aminobutyric acid (GABA), which 
ultimately inhibit the transmission of excitatory pain impulses.2,42,43
The hyperalgesia, allodynia and other features associated with 
neuropathic pain disorders may be explained by the following changes 
that occur in the nervous system following nerve damage:
1.  Peripheral sensitisation. Chemical medicators such as substance 
P, bradykinin and histamine may sensitise nociceptors to transmit 
stimuli perceived as painful, although the stimulus may be much 
lower than the original pain activation threshold.43
2.  Ectopic discharges. An accumulation of sodium channels at the site 
of nerve injury causes repetitive firing of injured axons, which may 
be perceived as spontaneous pain.2,43
3.  Central sensitisation.41,44 Central sensitisation is a state of 
increased sensitivity of dorsal horn neurons so that their activation 
threshold is reduced. It follows the activation of the N-methyl 
D-aspartate (NMDA) receptor by the neurotransmitter glutamate 
and the subsequent influx of calcium through the voltage-gated 
calcium channels into the neuron. A complex set of intracellular 
events following this calcium influx lead to altered gene expression 
and long-term neuronal changes, and a more sensitive nervous 
system.42,44 Expression of the voltage-gated calcium channels 
is increased following nerve injury.6,45 Clinical support for this 
phenomenon arises from the analgesic efficacy of α2-δ voltage-
gated calcium channels antagonists (see later) in patients with 
NP disorders.46 The pain may also spread beyond the dermatome 
of an affected nerve to adjacent segments as a result of central 
sensitisation, previously thought to be an indication of “hysteria”.8
4.  Central reorganisation. After nerve injury, pain fibres in the spinal 
cord may reorganise, such that sections that normally receive 
only painful stimuli from the peripherary via C fibres now receive 
non-painful stimuli from the Aß-fibres (due to “sprouting” of Aß-
terminals into the superficial lamina of the dorsal horn). Thus, even 
light touch may now be perceived as painful, explaining the clinical 
phenomenon of allodynia.4,8,41
5.  Loss of inhibitory control. Peripheral nerve injury may also cause 
a reduction in the activity of the spinal inhibitory pathways which 
contributes to abnormal pain sensitivity in patients with NP.41,42,43 
Together with the other mechanisms, it is associated with increased 
excitability in the flow of pain impulses through the central nervous 
system, and may manifest as spontaneous pain.
6.  Nerve injury may, in some individuals, be associated with an 
increased expression of α-adreno-receptors in injured axons. This 
phenomenon, together with sprouting of sympathetic axons onto 
the dorsal root ganglion, give rise to sympathetically maintained 
pain, e.g. as in complex regional pain syndrome.
Management of neuropathic pain
Management of neuropathic pain is symptomatic when the underlying 
condition causing the pain cannot be removed.6,8,34,47–51 In this scenario, 
chronic NP becomes a disease in its own right and which is managed 
accordingly, rather than cured (similar to other chronic disorders such 
as hypertension and diabetes mellitus).52 Clinicians must remain aware 
of the high rate of comorbidity of NP with sleep disorders, anxiety and 
mood disorders.37 NP may also be present with other types of pain 
requiring particular management, e.g. a patient with chronic neck pain 
with both osteoarthritis and a radiculopathy.
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The comprehensive management of a patient with NP is based on the 
biopsychosocial approach and may include conservative modalities 
such as physiotherapy, exercise, sleep hygiene, transcutaneous 
electrical nerve stimulation (TENS), etc. Rigorous evidence supporting 
the efficacy of these modalities is limited, but they should be 
considered when appropriate.
Patient education, support and reassurance is a critical component of 
optimal management. It also includes the setting of realistic treatment 
goals.
Cognitive behavioural therapy (CBT) assists patients to identify 
maladaptive thinking patterns and to develop the ability to challenge 
errors of thinking. Objectives in a CBT programme include:
• change view of pain from overwhelming to manageable
• engage in pleasurable distracting activities
• teach specific coping skills
Since non-pharmacological treatment is often not sufficient, rational 
pharmacotherapy is usually indicated, although it is also limited in its 
efficacy (only ± 40–50% of patients obtain partial pain relief).3,47–49 A 
reduction of 30% in pain intensity (on an 11-point numerical rating 
scale) is regarded as clinically relevant and equivalent to ratings 
of “moderate relief” and “much improved”. Drug-related adverse 
effects are common because many patients are older and take 
other medications for comorbid illnesses. Simple analgesics such as 
paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs and 
coxibs) are ineffective in pure NP.6
Currently five medications have been approved by the US Food and 
Drug Administration (FDA) for the treatment of NP, namely:
·  Postherpetic neuralgia: lidocaine patch (5%), gabapentin, 
pregabalin
· Painful diabetic polyneuropathy: pregabalin and duloxetine
· Trigeminal neuralgia: carbamazepine
The majority of randomised controlled trials (RCTs) have investigated 
patients with postherpetic neuralgia (PHN) and painful diabetic 
peripheral neuropathy (PDPN), mostly only for a period of three 
months or shorter. The applicability of these results to other NP 
disorders is difficult to determine, and some types of NP patients may 
respond differently. However, the first-line medications have been 
tested with different types of NP, and extrapolation of efficacy to other 
types of NP is probably reasonable and often clinically necessary.34,47,48 
Treatment efficacy can be expressed in the number-needed-to-treat 
(NNT) to obtain at least 50% pain relief in one patient. The NNT 
approach has various limitations, such as lacking other important 
outcomes, e.g. improvement in function and quality of life. Most RCTs 
are short-term studies, and there may be methodological differences 
between different RCTs that may influence NNT calculations, which 
are done retrospectively with often different cut-off points for defining 
pain relief.48 It should be remembered that the NNT does not focus on 
intolerable side effects, and that the numbers needed to harm (NNH) 
necessitating withdrawal from a trial is also important in evaluating 
and comparing medication efficacy.2 The available studies evaluating 
adjuvant analgesics in NP are mostly placebo-controlled and do not 
compare specific agents. The following guidelines are based on the 
most recent recommendations of the IASP Neuropathic Pain Special 
Interest Group.47
First-line medications:
• Tricyclic antidepressants (TCAs):
  The analgesic effect of TCAs is independent of its antidepressive 
effect and has repeatedly been shown to reduce NP.53 TCAs 
(NNT = 3) are more effective than SSRIs (NNT = 6, 7) and their 
analgesic action may be due to noradrenaline and serotonin 
reuptake inhibition (enhancing descending inhibition) and NMDA 
receptor blockade.54 The main problem with TCAs is their adverse 
effects, including anticholinergic effects (e.g. constipation, blurred 
vision, dry mouth and urinary retention), sedation and orthostatic 
hypotension. Cognitive impairment and gait disturbances may 
predispose to falls in older patients and cardiotoxicity necessitates 
a screening electrocardiogram in patients over 40 years of age, and 
avoidance in patients with ischaemic heart disease.6,47 TCAs must 
be used cautiously when there is a risk for suicide.
• Selective serotonin and norepinephrine reuptake inhibitors (SSNRIs):
  Duloxetine is a SSNRI and has demonstrated significant pain 
relief compared with placebo in RCTs, (also in an open-label study 
over 52 weeks) in patients with PDPN.55 Duloxetine has a more 
favourable side effect profile in comparison with TCAs. Fewer 
studies have been done on Venlafaxine (another SSNRI). The NNT 
of the SSNRIs is regarded as 4– 5.5.6,48
• Calcium channel α2-δ ligands:
  Both gabapentin and pregabalin have a unique mechanism of 
action that differs from other anticonvulsants. They bind to the 
α2-δ subunit of the voltage-gated calcium channels, resulting in 
the inhibition of glutamate and substance P release in the spinal 
dorsal horn.56 The α2-δ subunits of the voltage-gated calcium 
channels are widely distributed throughout the peripheral and 
central nervous system, and upregulation of the α2-δ subunits are 
thought to play an important role in the central sensitisation process 
after damage to the nervous system.57 Both gabapentin and 
pregabalin have proven efficacy in RCTs of various neuropathic 
pain disorders. Most of the larger studies were done on patients 
with PHN and PDPN.3,47,48,57 Pregabalin has a higher binding affinity 
for the α2-δ subunit than gabapentin, and the twice daily dosing 
and linear pharmacokinetic profile makes it more convenient 
for prescriber and user.47,57 However, the overall efficacy and 
tolerability of gabapentin and pregabalin are very similar. More 
common side effects include somnolence, dizziness and mild 
peripheral oedema.34 The NNT for gabapentin is comparable to that 
of pregabalin, and mostly ranges from 3.1 to 5.4 depending on the 
dosages used in the particular study.48
• 5% lidocaine patch (not available in South Africa):
  It has proven efficacy in patients with focal PHN and allodynia, and 
has been FDA approved for this indication.58
Second-line medications:
•  Opioid analgesics and tramadol have demonstrated efficacy 
in NP patients in a recent meta-analysis.59 They may be used 
as second-line treatment, alone or in combination with first-line 
medication(s) in patients with an inadequate response to first-line 
pharmacotherapy. They may also be used as first-line medications 
in patients with severe acute neuropathic pain when prompt pain 
relief is required and in patients with severe neuropathic cancer 
pain.47
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Tramadol is a weak opioid and a mixed serotonin/noradrenaline 
reuptake inhibitor. Three RCTs of tramadol for neuropathic pain 
have yielded significant evidence for its use in NP with an overall 
NNT of 3,9.6,48 There is an increased risk of seizures in patients 
treated with tramadol who have a history of seizures, or who are 
also receiving antidepressants.34 The role of strong opioids in NP has 
been controversial, but a recent meta-analysis provided convincing 
evidence of benefit, with the NNT ranging from 2.5 to 2.6.6,48,59 Current 
evidence supports the use of strong opioids in a carefully selected 
subset of patients with chronic and resistant NP. A detailed assessment 
by an experienced pain clinician is necessary and only sustained-
release opioids, e.g. transdermal fentanyl, and sustained release oral 
morphine, should be used.60,61 Short-acting and injectable opioids may 
predispose to tolerance and dependence. Effective pain relief should 
be accompanied by improved physical and psychosocial functioning.
The incidence of true addiction to strong opioids in the management 
of chronic pain is low if the medication is appropriately prescribed 
and monitored by the prescribing physician. Opioids should not be 
prescribed to patients with a personal or family history of substance 
abuse, with comorbid psychiatric comorbidity, or where the pain is 
“psychologically maintained”.60–62 Therapy with strong opioids in chronic 
NP is not regarded as lifelong. There is evolving data on the potential 
immunological, endocrine and other effects of long-term treatment with 
opioids and the line between appropriate caution and excessive “opio-
phobia” is a fine and evolving one.63
Third-line medications:
These are medications for which there is much less evidence 
of efficacy than for first- and second-line medications.2,47,48 Such 
medications include the following:
•  Anticonvulsants: carbamazepine, oxcarbazepine, valproic acid, 
phenytoin, lamotrigine
• Antidepressants: paroxetine, citalopram, bupropion
• NMDA receptor antagonists: ketamine
• Capsaici.
Carbamazepine is considered first-line therapy for trigeminal neuralgia 
with a NNT of 1,7.48 Although it has been recommended for patients 
with other types of NP who do not respond to gabapentin or pregabalin, 
it has yielded inconsistent results in RCTs of other NP conditions.34,47,48 
Carbamazepine is associated with ataxia and cognitive impairment, 
and induces various cytochrome-P450 liver enzymes, accelerating 
the metabolism of coadministered drugs and resulting in many drug 
interactions.51
Lamotrigine is a third-line anticonvulsant which has shown modest 
efficacy for HIV-associated sensory neuropathy.64
Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine 
and citalopram are not as effective as SSNRIs and TCAs. They have a 
NNT of 6.7 6
NMDA antagonists such as ketamine have thus far shown limited 
efficacy and often have intolerable side effects.
Capsaicin, an ingredient of hot peppers, has shown mixed results in 
RCTs. It is applied topically and has shown efficacy in PHN, PDPN and 
in mixed NP conditions, with a NNT ranging from 4.6 to 12 (average 
6.7).48 Capsaicin inhibits the release of substance-P from nerve 
Figure 1:  Proposed algorithm for management of neuropathic pain in primary 
care4,6,34,41,42,47,48,50
















Monotherapy with tramadol or slow-
release opioid
Add tramadol or slow-release opioid
Ineffective
Intolerable
 Consider trial of third-line medication
Trigeminal neuralgia carbamazepine
Focal NP trial of capsaicin
endings, with a gradual analgesic effect, which may take effect only 
after 2–4 weeks with consistent application. The most common side 
effect is burning at the site of application, which may have a significant 
impact on patient compliance.
Rational polypharmacy is often appropriate in patients with NP. More 
than one mechanism is often involved in NP and the use of multiple 
medications with different mechanisms may be of substantial benefit to 
some patients.50
Interventional pain management
Existing pharmacologic treatments are of limited efficacy. Despite the 
best care and trials of therapy, NP will remain inadequately relieved for 
40–60% of patients, and 10–15% of NP patients are regarded as truly 
refractory to all forms of pharmacotherapy.44,47,51,65
Nerve block procedures may, in selected patients, be of value earlier 
in the course of NP, e.g. sympathetic nerve blocks in early complex 
regional pain syndrome, to facilitate physiotherapy and rehabilitation. 
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There is little controlled evidence to confirm the efficacy of other nerve 
blocks in NP.6,65
Pulsed radiofrequency is a nondestructive procedure that may relieve 
chronic NP in carefully selected patients, but more evidence is needed 
before official recommendations for this procedure in guidelines will be 
appropriate.66
More invasive therapy may be considered for patients with refractory 
and intractable NP without surgically treatable pathology. These 
include augmentative neuromodulation therapy, e.g. peripheral, spinal 
cord and motor cortex stimulation, intrathecal drug delivery systems 
and ablative neurosurgical procedures.44 The best success rates 
in this category are for trigeminal ganglion balloon decompression 
and microvascular decompression, both procedures for trigeminal 
neuralgia.6,67
Conclusion
Neuropathic pain is an important cause of intractable and severe 
pain. It remains however an underdiagnosed and undertreated entity 
in primary and other levels of care. Due to its multifactorial aetiology 
involving different mechanisms and a high prevalence of comorbidities, 
various medications from different classes may be necessary to 
manage NP. The proposed algorithm provides the primary care 
practitioner with appropriate pharmacological guidelines as part of a 
multidimensional biopsychosocial approach.
Neuropathic pain research and management is an evolving science. 
Future strategies should include identification of treatments most 
effective for a particular clinical profile and an increased emphasis 
on prevention. Further validated tools for the diagnosis of NP are 
necessary to increase awareness and improve management of a 
difficult but relevant health care problem.6,34,51  
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